Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Non Operating Investment Income: 2020-2025

Historic Non Operating Investment Income for C4 Therapeutics (CCCC) over the last 4 years, with Jun 2025 value amounting to -$73,000.

  • C4 Therapeutics' Non Operating Investment Income fell 21.67% to -$73,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $410,000, marking a year-over-year decrease of 69.27%. This contributed to the annual value of $180,000 for FY2024, which is 95.51% down from last year.
  • Per C4 Therapeutics' latest filing, its Non Operating Investment Income stood at -$73,000 for Q2 2025, which was down 630.00% from -$10,000 recorded in Q1 2025.
  • Over the past 5 years, C4 Therapeutics' Non Operating Investment Income peaked at $1.7 million during Q1 2023, and registered a low of -$2.9 million during Q1 2022.
  • Moreover, its 3-year median value for Non Operating Investment Income was $343,000 (2023), whereas its average is $410,700.
  • In the last 5 years, C4 Therapeutics' Non Operating Investment Income slumped by 12,500.00% in 2021 and then skyrocketed by 305.16% in 2022.
  • Over the past 5 years, C4 Therapeutics' Non Operating Investment Income (Quarterly) stood at -$620,000 in 2021, then surged by 305.16% to $1.3 million in 2022, then crashed by 38.92% to $777,000 in 2023, then slumped by 151.74% to -$402,000 in 2024, then fell by 21.67% to -$73,000 in 2025.
  • Its Non Operating Investment Income was -$73,000 in Q2 2025, compared to -$10,000 in Q1 2025 and -$402,000 in Q4 2024.